Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment - PubMed (original) (raw)

Comparative Study

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment

Simona Urbani et al. J Hepatol. 2008 Apr.

Erratum in

J Hepatol. 2008 Sep;49(3):483

Abstract

Background/aims: HCV-specific T cells in acute hepatitis C with subsequent chronic evolution are dysfunctional and most of them express PD-1. The aim of the study was to investigate to what extent the antiviral T cell function can be restored by reversing T cell exhaustion by PD-1/PD-L1 blockade and to assess whether this restoration is favored by IFN-alpha treatment.

Methods: PD-1 and PD-L1 expression was studied on T cells and dendritic cells, respectively, of 14 patients with acute hepatitis C and different evolutions of infection. The effect of anti-PD-L1 was analyzed on proliferation, cytokine production and cytolytic activity of CD4 and CD8 T cells.

Results: While PD-1 expression dropped concurrently with spontaneous or IFN-alpha induced HCV-RNA decline, PD-L1 levels on dendritic cells increased during IFN-alpha treatment. Anti-PD-L1 antibodies improved expansion and cytokine production but not the cytolytic activity of HCV-specific T cells. This restoration tended to be greater at lower levels of viremia and PD-1 expression and during PEG-IFNalpha treatment.

Conclusions: PD-1/PD-L1 blockade has an immunoregulatory activity which may synergize with the antiviral effect of IFN-alpha therapy and should be thus explored further in long-lasting chronic HCV infections in the perspective of improving the efficacy of available antiviral treatments.

PubMed Disclaimer

Cited by

T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C.
Caraballo Cortés K, Osuch S, Perlejewski K, Radkowski M, Janiak M, Berak H, Rauch A, Fehr JS, Hoffmann M, Günthard HF, Metzner KJ. Caraballo Cortés K, et al. Open Forum Infect Dis. 2023 Oct 21;10(11):ofad514. doi: 10.1093/ofid/ofad514. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 37953817 Free PMC article.
Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection.
Su M, Ye T, Wu W, Shu Z, Xia Q. Su M, et al. Dig Dis. 2024;42(1):53-60. doi: 10.1159/000534535. Epub 2023 Oct 11. Dig Dis. 2024. PMID: 37820605 Free PMC article. Review.
Individual Epitope-Specific CD8+ T Cell Immune Responses Are Shaped Differently during Chronic Viral Infection.
Klein S, Mischke J, Beruldsen F, Prinz I, Antunes DA, Cornberg M, Kraft ARM. Klein S, et al. Pathogens. 2023 May 14;12(5):716. doi: 10.3390/pathogens12050716. Pathogens. 2023. PMID: 37242386 Free PMC article.
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.
Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Singh V, et al. Front Pharmacol. 2021 Dec 23;12:790963. doi: 10.3389/fphar.2021.790963. eCollection 2021. Front Pharmacol. 2021. PMID: 35002724 Free PMC article. Review.
Nanocarrier vaccines for SARS-CoV-2.
Machhi J, Shahjin F, Das S, Patel M, Abdelmoaty MM, Cohen JD, Singh PA, Baldi A, Bajwa N, Kumar R, Vora LK, Patel TA, Oleynikov MD, Soni D, Yeapuri P, Mukadam I, Chakraborty R, Saksena CG, Herskovitz J, Hasan M, Oupicky D, Das S, Donnelly RF, Hettie KS, Chang L, Gendelman HE, Kevadiya BD. Machhi J, et al. Adv Drug Deliv Rev. 2021 Apr;171:215-239. doi: 10.1016/j.addr.2021.01.002. Epub 2021 Jan 9. Adv Drug Deliv Rev. 2021. PMID: 33428995 Free PMC article.

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment - PubMed (original) (raw)